Cargando…

Selective serotonin reuptake inhibition modulates response inhibition in Parkinson’s disease

Impulsivity is common in Parkinson’s disease even in the absence of impulse control disorders. It is likely to be multifactorial, including a dopaminergic ‘overdose’ and structural changes in the frontostriatal circuits for motor control. In addition, we proposed that changes in serotonergic project...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ye, Zheng, Altena, Ellemarije, Nombela, Cristina, Housden, Charlotte R., Maxwell, Helen, Rittman, Timothy, Huddleston, Chelan, Rae, Charlotte L., Regenthal, Ralf, Sahakian, Barbara J., Barker, Roger A., Robbins, Trevor W., Rowe, James B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2014
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3959561/ https://www.ncbi.nlm.nih.gov/pubmed/24578545 http://dx.doi.org/10.1093/brain/awu032

Ejemplares similares

Improving Response Inhibition in Parkinson’s Disease with Atomoxetine
por: Ye, Zheng, et al.
Publicado: (2015)

Predicting beneficial effects of atomoxetine and citalopram on response inhibition in Parkinson's disease with clinical and neuroimaging measures
por: Ye, Zheng, et al.
Publicado: (2016)

Atomoxetine restores the response inhibition network in Parkinson’s disease
por: Rae, Charlotte L., et al.
Publicado: (2016)

Targeting impulsivity in Parkinson’s disease using atomoxetine
por: Kehagia, Angie A., et al.
Publicado: (2014)

Improving response inhibition systems in frontotemporal dementia with citalopram
por: Hughes, Laura E., et al.
Publicado: (2015)

White matter pathology in Parkinson's disease: The effect of imaging protocol differences and relevance to executive function
por: Rae, Charlotte L., et al.
Publicado: (2012)

Multiple Modes of Impulsivity in Parkinson's Disease
por: Nombela, Cristina, et al.
Publicado: (2014)

The medial frontal-prefrontal network for altered awareness and control of action in corticobasal syndrome
por: Wolpe, Noham, et al.
Publicado: (2014)

Perseveration and Choice in Parkinson's Disease: The Impact of Progressive Frontostriatal Dysfunction on Action Decisions
por: Hughes, Laura E., et al.
Publicado: (2013)

Different decision deficits impair response inhibition in progressive supranuclear palsy and Parkinson’s disease
por: Zhang, Jiaxiang, et al.
Publicado: (2016)

ROS-Scavenging Selenofluoxetine Derivatives Inhibit In Vivo Serotonin Reuptake
por: Ribaudo, Giovanni, et al.
Publicado: (2022)

Atomoxetine and citalopram alter brain network organization in Parkinson’s disease
por: Borchert, Robin J, et al.
Publicado: (2019)

Atomoxetine Enhances Connectivity of Prefrontal Networks in Parkinson's Disease
por: Borchert, Robin J, et al.
Publicado: (2016)

Locus coeruleus integrity and the effect of atomoxetine on response inhibition in Parkinson’s disease
por: O’Callaghan, Claire, et al.
Publicado: (2021)

Sentiment Analysis of Online Reviews for Selective Serotonin Reuptake Inhibitors and Serotonin–Norepinephrine Reuptake Inhibitors
por: Compagner, Chad, et al.
Publicado: (2021)

Expression of 22 serotonin-related genes in rat brain after sub-acute serotonin depletion or reuptake inhibition
por: Näslund, Jakob, et al.
Publicado: (2020)

The serotonin reuptake inhibitor Fluoxetine inhibits SARS-CoV-2 in human lung tissue
por: Zimniak, Melissa, et al.
Publicado: (2021)

Clinical pharmacology of serotonin selective reuptake inhibitors /
por: Preskorn, Sheldon
Publicado: (1996)

Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia
por: Welsch, Patrick, et al.
Publicado: (2018)

Selective serotonin reuptake inhibitors and Alzheimer’s disease
por: Mdawar, Bernadette, et al.
Publicado: (2019)

Inhibition of the Serotonin Transporter Is Altered by Metabolites of Selective Serotonin and Norepinephrine Reuptake Inhibitors and Represents a Caution to Acute or Chronic Treatment Paradigms
por: Krout, Danielle, et al.
Publicado: (2016)

Differential Potency of Venlafaxine, Paroxetine, and Atomoxetine to Inhibit Serotonin and Norepinephrine Reuptake in Patients With Major Depressive Disorder
por: Aldosary, Fahad, et al.
Publicado: (2021)

Effect of selective serotonin reuptake inhibitor discontinuation on anxiety-like behaviours in mice
por: Collins, Helen M, et al.
Publicado: (2022)

Effects of selective serotonin reuptake inhibitor treatment on plasma oxytocin and cortisol in major depressive disorder
por: Keating, Charlotte, et al.
Publicado: (2013)

Serotonin syndrome triggered by postoperative administration of serotonin noradrenaline reuptake inhibitor (SNRI)
por: Takata, Junko, et al.
Publicado: (2019)

Effect of Serotonin Reuptake Inhibitors on Pulmonary Hemodynamics in Humans
por: Pleym, Hilde, et al.
Publicado: (2011)

Serotonin reuptake inhibitor antidepressants (SSRIs) against atherosclerosis
por: Wozniak, Greta, et al.
Publicado: (2011)

Heart Rate Recovery and Selective Serotonin Reuptake Inhibitors
por: Cerit, Levent
Publicado: (2016)

Selective serotonin reuptake inhibitor-induced galactorrhea with hyperprolactinemia
por: Bhattacharjee, Subir, et al.
Publicado: (2021)

Confounding by Indication in Studies of Selective Serotonin Reuptake Inhibitors
por: Lee, Jimin, et al.
Publicado: (2022)

Selective serotonin reuptake inhibitor escitalopram inhibits 5-HT(3) receptor currents in NCB-20 cells
por: Park, Yong Soo, et al.
Publicado: (2019)

Fatigue-related impairments in oculomotor control are prevented by norepinephrine-dopamine reuptake inhibition
por: Connell, Charlotte J. W., et al.
Publicado: (2017)

Transient Serotonin Syndrome Caused by Concurrent Use of Tramadol and Selective Serotonin Reuptake Inhibitor
por: Shakoor, Muhammad Tariq, et al.
Publicado: (2014)

Selection and stopping in voluntary action: A meta-analysis and combined fMRI study()
por: Rae, Charlotte L., et al.
Publicado: (2014)

Selective serotonin reuptake inhibitors, and serotonin and norepinephrine reuptake inhibitors for anxiety, obsessive-compulsive, and stress disorders: A 3-level network meta-analysis
por: Gosmann, Natan Pereira, et al.
Publicado: (2021)

The Efficacy and Safety of Selective Serotonin Reuptake Inhibitors and Serotonin-Norepinephrine Reuptake Inhibitors in the Treatment of Menopausal Hot Flashes: A Systematic Review of Clinical Trials
por: Azizi, Marzieh, et al.
Publicado: (2022)

Clinical Utility of Semistructured Interview and Scales to Assess Withdrawal Syndromes With Dose Reduction or Discontinuation of Selective Serotonin Reuptake Inhibitors or Serotonin Norepinephrine Reuptake Inhibitors
por: Cosci, Fiammetta, et al.
Publicado: (2022)

How Sleep Affects Daytime Functioning: The Latest Insights from Different Patient and Age Groups
por: Altena, Ellemarije, et al.
Publicado: (2021)

Overcoming Resistance to Selective Serotonin Reuptake Inhibitors: Targeting Serotonin, Serotonin-1A Receptors and Adult Neuroplasticity
por: Vahid-Ansari, Faranak, et al.
Publicado: (2019)

Difficulty in Repurposing Selective Serotonin Reuptake Inhibitors and Other Antidepressants with Functional Inhibition of Acid Sphingomyelinase in COVID-19 Infection
por: Le Corre, Pascal, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ta2pjpegil55qc2iioko973pu0